Evidence map›Paper›PMID 39246390›Full record

ArticleImmunomedicine2024

Engineered Immunologic Niche Monitors Checkpoint Blockade Response and Probes Mechanisms of Resistance.

Ravi M Raghani, Russell R Urie, Jeffrey A Ma, Guillermo Escalona, Ian A Schrack, Katarina M DiLillo, Pridvi Kandagatla, Joseph T Decker, Aaron H Morris, Kelly B Arnold and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ravi M RaghaniDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.
Russell R UrieDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.
Jeffrey A MaDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.
Guillermo EscalonaDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.
Ian A SchrackDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.
Katarina M DiLilloDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.
Pridvi KandagatlaDepartment of Surgery, Washington University, St. Louis, Missouri.
Joseph T DeckerDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.
Aaron H MorrisDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.
Kelly B ArnoldDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.
Jacqueline S JerussDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.
Lonnie D SheaDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.

Funding

Proteogenomics of Cancer Training ProgramT32CA140044 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAO, ARVIND, SARTOR, MAUREEN AGNES · 2010 to 2024
$3.9M
Identifying intercellular circuits driving cell phenotypes within a nicheR01CA243916 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JERUSS, JACQUELINE SARA, SHEA, LONNIE D · 2019 to 2023
$2.3M
Mitochondrial NAD+ in Acute Myeloid LeukemiasR01CA272490 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI Xiaolu Ang Cambronne · 2023 to 2026
$2.1M
Measuring Signaling Pathway Dynamics During Tissue Growth in HydrogelsR01CA214384 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JERUSS, JACQUELINE SARA, SHEA, LONNIE D · 2017 to 2021
$1.8M
Tissue engineering tools for monitoring the cellular and molecular response to therapyR01CA272940 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JACQUELINE SARA JERUSS, Lonnie D Shea · 2023 to 2026
$1.7M
Chimeric Antigen Receptor T Cell Design Through Living Cell Systems BiologyK01EB028877 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DECKER, JOSEPH THOMAS · 2019 to 2022
$492k
NCI NIH HHS R01 CA214384NCI NIH HHS R01 CA243916NCI NIH HHS R01 CA272490NCI NIH HHS R01 CA272940NCI NIH HHS T32 CA140044NIBIB NIH HHS K01 EB028877
6 · The paper itself

Abstract

Antibodies to programmed cell death protein1 (anti-PD-1) have become a promising immunotherapy for triple negative breast cancer (TNBC), blocking PD-L1 signaling from pro-tumor cells through T cell PD-1 receptor binding. Nevertheless, only 10-20% of PD-L1

Indexed as

biomaterialscheckpoint blockadeimmunotherapy resistancemetastasistherapy monitoring

Identifiers

PMID39246390
PMCPMC11376346

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.